Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies

References

• Gorovits B, Alley SC, Bilic S, Booth B, Kaur S, Oldfield P, Purushothama S, Rao C, Shord S, Siguenza P. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis 2013; 5:997 - 1006; http://dx.doi.org/10.4155/bio.13.38; PMID: 23641692
   PubMed Web of Science ®Google Scholar
• Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov 2013; 12:329 - 32; http://dx.doi.org/10.1038/nrd4009; PMID: 23629491
   PubMed Web of Science ®Google Scholar
• Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R, Dumontet C, Morariu-Zamfir R, Lambert JM, Ozoux ML, et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs 2012; 30:1121 - 31; http://dx.doi.org/10.1007/s10637-011-9670-0; PMID: 21519855
   PubMed Web of Science ®Google Scholar
• Rowe JM, Löwenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood 2013; 121:4838 - 41; http://dx.doi.org/10.1182/blood-2013-03-490482; PMID: 23591788
   PubMed Web of Science ®Google Scholar
• Lu D, Joshi A, Wang B, Olsen S, Yi JH, Krop IE, Burris HA, Girish S. An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. Clin Pharmacokinet 2013; 52:657 - 72; http://dx.doi.org/10.1007/s40262-013-0060-y; PMID: 23553425
   PubMed Web of Science ®Google Scholar
• Pascual MH, Verdier P, Malette P, Mnich J, Ozoux ML. Validation of an immunoassay to selectively quantify the naked antibody of a new Antibody Drug Conjugate--SAR566658--for pharmacokinetic interpretation improvement. J Immunol Methods 2013; 396:140 - 6; http://dx.doi.org/10.1016/j.jim.2013.06.012; PMID: 23892158
   PubMed Web of Science ®Google Scholar
• Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49:633 - 59; http://dx.doi.org/10.2165/11535960-000000000-00000; PMID: 20818831
   PubMed Web of Science ®Google Scholar
• Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93:2645 - 68; http://dx.doi.org/10.1002/jps.20178; PMID: 15389672
   PubMed Web of Science ®Google Scholar
• EMA [Internet] Refusal assessment report for Mylotarg, Procedure No. EMEA/H/C/000705 2008 [Cited 2014 Feb 20] Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000705/WC500070677.pdf
   Google Scholar
• Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49:493 - 507; http://dx.doi.org/10.2165/11531280-000000000-00000; PMID: 20608753
   PubMed Web of Science ®Google Scholar
• Drugs@FDA:Kadcyla [Internet] Application Number: 125427orig1s000, Clinical Pharmacology and Biopharmaceutics Reviews [Cited 2014 Feb 20] Available from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125427Orig1s000ClinPharmR.pdf
   Google Scholar
• Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 2005; 56:361 - 9; http://dx.doi.org/10.1007/s00280-005-1026-z; PMID: 15868146
   PubMed Web of Science ®Google Scholar
• Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006; 11:81 - 8; http://dx.doi.org/10.1016/S1359-6446(05)03638-X; PMID: 16478695
   PubMed Web of Science ®Google Scholar
• Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 2001; 41:1206 - 14; http://dx.doi.org/10.1177/00912700122012751; PMID: 11697753
   PubMed Web of Science ®Google Scholar
• Drugs@FDA:Adcetris [Internet] Application Number: 125388Orig1s000, Clinical Pharmacology and Biopharmaceutics Reviews [Cited 2014 Feb 20] Available from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125388Orig1s000ClinPharmR.pdf
   Google Scholar
• Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, Burris Iii HA, LoRusso PM, Yi JH, Saad O, et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 2012; 69:1229 - 40; http://dx.doi.org/10.1007/s00280-011-1817-3; PMID: 22271209
   PubMed Web of Science ®Google Scholar
• Ferte C, Soria JC, Penel N. Dose-levels and first signs of efficacy in contemporary oncology Phase 1 clinical trials. PLoS One 2011; 6:e16633; http://dx.doi.org/10.1371/journal.pone.0016633; PMID: 21415927
   PubMedGoogle Scholar
• Roberts SA, Andrews PA, Blanset D, Flagella KM, Gorovits B, Lynch CM, Martin PL, Kramer-Stickland K, Thibault S, Warner G. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology. Regul Toxicol Pharmacol 2013; 67:382 - 91; http://dx.doi.org/10.1016/j.yrtph.2013.08.017; PMID: 24012707
   PubMed Web of Science ®Google Scholar
• Annunziata CM, Kohn EC, LoRusso P, Houston ND, Coleman RL, Buzoianu M, Robbie G, Lechleider R. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs 2013; 31:77 - 84; http://dx.doi.org/10.1007/s10637-012-9801-2; PMID: 22370972
   PubMed Web of Science ®Google Scholar
• Haddish-Berhane N, Shah DK, Ma D, Leal M, Gerber HP, Sapra P, Barton HA, Betts AM. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. J Pharmacokinet Pharmacodyn 2013; 40:557 - 71; http://dx.doi.org/10.1007/s10928-013-9329-x; PMID: 23933716
   PubMed Web of Science ®Google Scholar
• Coiffier B, Morschhauser F, Dupuis J, Haioun C, Laine F, Houot R, et al. Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti-CD19 DM4-loaded antibody drug conjugate (ADC), in patients (pts) with CD19 positive relapsed/refractory b-cell non-Hodgkin's lymphoma. J Clin Oncol 2012; 30:Suppl. 1 8057
   Web of Science ®Google Scholar
• Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, et al, Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012; 379:1508 - 16; http://dx.doi.org/10.1016/S0140-6736(12)60485-1; PMID: 22482940
   PubMed Web of Science ®Google Scholar
• Sapra P, Betts A, Boni J. Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates. Expert Rev Clin Pharmacol 2013; 6:541 - 55; http://dx.doi.org/10.1586/17512433.2013.827405; PMID: 23978126
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, U.S. Department of Health and Human Services,, Center for Drug Evaluation and Research (CDER), July 2005
   Google Scholar
• Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol 2010; 28:2085 - 93; http://dx.doi.org/10.1200/JCO.2009.25.1900; PMID: 20308665
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Wolf JL, Garcia J, Gharibo M, Jagannath S, Manfredi D, et al. Efficacy analysis from phase I study of lorvotuzumab mertansine (IMGN901), used as monotherapy, in patients with heavily pre-treated CD56-positive multiple myeloma - A preliminary efficacy analysis. Blood 2010; 116:21
   Google Scholar
• Chanan-Khan AA, Jagannath S, Heffner LT, Avigan D, Lee KP, Lutz RJ, et al. Phase I study of BT062 given as repeated single dose once every 3 weeks in patients with relapsed or relapsed/refractory multiple myeloma. Blood 2009; 114:22
   Google Scholar
• Galsky MD, Eisenberger M, Moore-Cooper S, Kelly WK, Slovin SF, DeLaCruz A, Lee Y, Webb IJ, Scher HI. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 2008; 26:2147 - 54; http://dx.doi.org/10.1200/JCO.2007.15.0532; PMID: 18362364
   PubMed Web of Science ®Google Scholar
• Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28:2698 - 704; http://dx.doi.org/10.1200/JCO.2009.26.2071; PMID: 20421541
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Kantoff PW, Mega AE, Vogelzang NJ, Stephenson J, Fleming MT, Stambler N, Petrini M, Blattman S, Israel RJ. Prostate- specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane. J Clin Oncol 2013; 31 Suppl. 1
   Google Scholar
• Sauter A, Kloft C, Gronau S, Bogeschdorfer F, Erhardt T, Golze W, Schroen C, Staab A, Riechelmann H, Hoermann K. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol 2007; 30:927 - 35; PMID: 17332932
   PubMed Web of Science ®Google Scholar

• Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, de Bono J, Schwartz G, Mays T, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003; 21:211 - 22; http://dx.doi.org/10.1200/JCO.2003.05.137; PMID: 12525512
   PubMed Web of Science ®Google Scholar
• Younes A, Kim S, Romaguera J, Copeland A, Farial SdeC, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol 2012; 30:2776 - 82; http://dx.doi.org/10.1200/JCO.2011.39.4403; PMID: 22753910
   PubMed Web of Science ®Google Scholar